What can reality TV teach us about clinical drug trials?

Health and medicine explained.
May 13 2009 11:33 AM

When the Lights Go Out

What can reality TV teach us about clinical drug trials?

(Continued from Page 1)

Unfortunately, surrogate endpoints can be problematic for two key reasons. First, their relation to the actual outcome of interest may be weak or nonexistent (just as impressing Donald Trump may fail to predict later business success); second, the intervention can improve the surrogate outcome but have bad side effects (just as the nonstop fancy dates that titillate viewers later lead to the couple's inevitable romantic disappointment).

Consider high serum cholesterol levels, which are a surrogate marker for later heart attacks. In the 1970s, a drug called clofibrate was discovered to markedly reduce cholesterol levels; unfortunately, a World Health Organization trial found it increased heart attacks. In 2002, the Women's Health Initiative trial showed hormone replacement caused blood clots and increased heart attacks by 29 percent, though it also made cholesterol numbers better. In 2006, Pfizer abruptly pulled the plug on its drug torcetrapib, which had cost roughly $1 billion to develop and had great effects on cholesterol levels—but also caused more heart attacks. Keep in mind that cholesterol levels, like blood pressure or levels of tumor markers in the blood, are at least considered "validated" markers.

Advertisement

In part, the increased focus on surrogate markers instead of hard outcomes came about in the 1990s, when the U.S. Food and Drug Administration was pressured to get HIV drugs to market rapidly for desperate patients, at the expense of using even "unvalidated" surrogate endpoints (like CD4 cell counts) that at the time were "reasonably likely" to predict benefit. For every turkey like clofibrate or torcetrapib, there are occasionally life-saving breakthroughs like protease inhibitors for HIV that may depend on a dizzying array of complicated surrogate endpoints.

How, then, can we encourage approval of drugs like protease inhibitors and cut the number of failures like clofibrate? The truth is that you can't, just like you can't easily figure out how to guarantee a happy marriage or find a surefire pop icon. You do the best with the information you have, then wait and see. In his terrific 2004 book Powerful Medicines, Jerry Avorn proposed a two-phased drug evaluation process in which "the initial FDA approval of a drug should be seen as the beginning of an intensive period of assessment, not the end." No doctor, he writes, would ever start a patient on a new medicine without scheduling any kind of follow-up, but that's exactly what the U.S. health care system now does.

The other way to help, of course, is to maintain the special environment that existed during the drug trial. During the yearlong intervention phase of the MTA study, kids got ideal therapy, medication oversight, and personal attention from their doctors, but once the study ended, many families simply bagged the drugs and therapy that may have been helping. So it also comes as no surprise they weren't better eight years later. Improving so-called compliance with treatment is a huge challenge (half of patients don't take their medicines) and may mitigate some problems with surrogate endpoints.

In the end, prescribing expensive and potentially dangerous drugs isn't exactly like a reality television show. But perhaps we should at least be equally skeptical of their outcomes until some time has gone by.

TODAY IN SLATE

Jurisprudence

Scalia’s Liberal Streak

The conservative justice’s most brilliant—and surprisingly progressive—moments on the bench.

Scotland Votes to Remain in U.K.

There’s a Way to Keep Ex-Cons Out of Prison That Pays for Itself. Why Don’t More States Use It?

The Music Industry Is Ignoring Some of the Best Black Women Singing R&B

Can Democrats Keep Counting on Republicans to Offend Women as a Campaign Strategy?

Culturebox

Theo’s Joint and Vanessa’s Whiskey

No sitcom did the “Very Special Episode” as well as The Cosby Show.

Television

The Other Huxtable Effect

Thirty years ago, The Cosby Show gave us one of TV’s great feminists.

Cliff Huxtable Explains the World: Five Lessons From TV’s Greatest Dad

Why Television Needs a New Cosby Show Right Now

  News & Politics
Weigel
Sept. 18 2014 8:20 PM A Clever Attempt at Explaining Away a Vote Against the Farm Bill
  Business
Moneybox
Sept. 18 2014 6:02 PM A Chinese Company Just Announced the Biggest IPO in U.S. History
  Life
The Slate Quiz
Sept. 18 2014 11:44 PM Play the Slate News Quiz With Jeopardy! superchampion Ken Jennings.
  Double X
Doublex
Sept. 18 2014 8:07 PM Crying Rape False rape accusations exist, and they are a serious problem.
  Slate Plus
Behind the Scenes
Sept. 18 2014 1:23 PM “It’s Not Every Day That You Can Beat the World Champion” An exclusive interview with chess grandmaster Fabiano Caruana.
  Arts
Brow Beat
Sept. 18 2014 4:33 PM The Top 5 Dadsplaining Moments From The Cosby Show
  Technology
Future Tense
Sept. 18 2014 6:48 PM By 2100 the World's Population Could Be 11 Billion
  Health & Science
Science
Sept. 18 2014 3:35 PM Do People Still Die of Rabies? And how do you know if an animal is rabid?
  Sports
Sports Nut
Sept. 18 2014 11:42 AM Grandmaster Clash One of the most amazing feats in chess history just happened, and no one noticed.